» Articles » PMID: 30172320

Identification of Breast Cancer Through Spectroscopic Analysis of Cell-membrane Sialic Acid Expression

Overview
Journal Anal Chim Acta
Publisher Elsevier
Specialty Chemistry
Date 2018 Sep 3
PMID 30172320
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Identification of specific and reliable biomarkers or unique characteristics is significant for cancer molecular diagnosis and cancer therapeutic assessment. As a biomarker, sialic acid expression in human biofluid or on cell surface is one of interest to determine the tumor malignancy and metastasis since it involves in many crucial metabolic processes. In this work, we aimed to develop a molecular diagnosis method to make it possible to distinguish human breast cancer and normal tissues by capturing rich spectral features of phenyboronic acid-based nanoprobe (MPBA@AgNP) when it binds to sialic acid on cell surface. We analyzed and found that the marker bands at 1074 and 1570 cm recorded by Surface-enhanced Raman spectroscopy (SERS) displayed discernible spectral differences in vitro cell lines. Density functional theory (DFT) was further used to explore and support the detailed changes of vibrational modes affected by sialic acid. This method is generally applicable by testing three types of in vitro cell lines (HepG2, Hela, BNL.CL2) and one pair of the tissue sections (cancer tissue and normal tissue) from the human breast regions. Besides, the area under receiver operating characteristic (ROC) curves for 1074 and 1572 cm are 0.9419 and 0.9023, confirming determination of the specific molecular expression by the spectral features holds potential promise for improving cancer detection accuracy. Furthermore, sialic acid expression and distribution acquired of breast tissues by confocal SERS mapping further indicated our method is possible for cancer early diagnosis and toward to real-time in vivo study.

Citing Articles

Recent progress in Surface-Enhanced Raman Spectroscopy detection of biomarkers in liquid biopsy for breast cancer.

Liu X, Jia Y, Zheng C Front Oncol. 2024; 14:1400498.

PMID: 39040452 PMC: 11260621. DOI: 10.3389/fonc.2024.1400498.


Recent Trends in SERS-Based Plasmonic Sensors for Disease Diagnostics, Biomolecules Detection, and Machine Learning Techniques.

Beeram R, Vepa K, Soma V Biosensors (Basel). 2023; 13(3).

PMID: 36979540 PMC: 10046859. DOI: 10.3390/bios13030328.


Altered Glycan Expression on Breast Cancer Cells Facilitates Infection by T3 Seroptype Oncolytic Reovirus.

Mohammed D, Koehler M, Dumitru A, Aravamudhan P, Sutherland D, Dermody T Nano Lett. 2021; 21(22):9720-9728.

PMID: 34762801 PMC: 8631336. DOI: 10.1021/acs.nanolett.1c03608.


So You Discovered a Potential Glycan-Based Biomarker; Now What? We Developed a High-Throughput Method for Quantitative Clinical Glycan Biomarker Validation.

Shipman J, Nguyen H, Desaire H ACS Omega. 2020; 5(12):6270-6276.

PMID: 32258861 PMC: 7114137. DOI: 10.1021/acsomega.9b03334.